Concord Biotech Limited (CONCORDBIO) — Cash Flow Reinvestment Rate
Concord Biotech Limited (CONCORDBIO) has a Cash Flow Reinvestment Rate of 0.45x as of March 2025, reinvesting Rs1.11 Billion (capex Rs1.11 Billion ) from operating cash flow of Rs2.47 Billion. See free cash flow generation of Concord Biotech Limited to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Concord Biotech Limited Cash Flow Reinvestment Rate (2020–2025)
Historical reinvestment intensity for Concord Biotech Limited across 6 annual periods. For the full cash flow conversion analysis, see Concord Biotech Limited (CONCORDBIO) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Concord Biotech Limited (2020–2025)
Year-by-year capital reinvestment analysis for Concord Biotech Limited. See financial flexibility index of Concord Biotech Limited to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (INR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | Rs1.11 Billion | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs856.88 Million | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs1.45 Billion | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs1.56 Billion | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs2.04 Billion | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | Rs1.55 Billion | — |